An approach to Interstitial Lung Disease / Diffuse Parenchymal Lung DiseaseThomas Kurian
YouTube link: https://youtu.be/gPr31qrivUc
An approach to Diffuse Parenchymal Lung disease / Interstitial Lung disease with emphasis on the idiopathic causes.
An approach to Interstitial Lung Disease / Diffuse Parenchymal Lung DiseaseThomas Kurian
YouTube link: https://youtu.be/gPr31qrivUc
An approach to Diffuse Parenchymal Lung disease / Interstitial Lung disease with emphasis on the idiopathic causes.
The discovery of malignant cells in pleural fluid
and/or parietal pleura signifies disseminated or
advanced disease and a reduced life expectancy in
patients with cancer.Median survival following
diagnosis ranges from 3 to 12 months and is
dependent on the stage and type of the underlying
malignancy. The shortest survival time is observed
in malignant effusions secondary to lung cancer
and the longest in ovarian cancer, while malignant
effusions due to an unknown primary have an
intermediate survival time.Historically, studies
showed that median survival times in effusions due
to carcinoma of the breast are 5-6 months.
However, more recent studies have suggested
longer survival times of up to 15 months. A
comparison of survival times in breast cancer
effusions in published studies to 1994 calculated
a median survival of 11 months.9
Currently, lung cancer is the most common
metastatic tumour to the pleura in men and breast
cancer in women.Together, both malignancies
account for 50- 65% of all malignant effusions. Lymphomas, tumours of the genitourinary
tract and gastrointestinal tract account for
a further 25% Pleural effusions from an
unknown primary are responsible for 15% of all
malignant pleural effusions.Few studies have
estimated the proportion of pleural effusions due to
mesothelioma: studies from 1975, 1985 and 1987
identified mesothelioma in 1/271, 3/472 and 22/592
patients, respectively, but there are no more recent
data to update this in light of the increasing incidence
of mesothelioma.
The discovery of malignant cells in pleural fluid
and/or parietal pleura signifies disseminated or
advanced disease and a reduced life expectancy in
patients with cancer.Median survival following
diagnosis ranges from 3 to 12 months and is
dependent on the stage and type of the underlying
malignancy. The shortest survival time is observed
in malignant effusions secondary to lung cancer
and the longest in ovarian cancer, while malignant
effusions due to an unknown primary have an
intermediate survival time.Historically, studies
showed that median survival times in effusions due
to carcinoma of the breast are 5-6 months.
However, more recent studies have suggested
longer survival times of up to 15 months. A
comparison of survival times in breast cancer
effusions in published studies to 1994 calculated
a median survival of 11 months.9
Currently, lung cancer is the most common
metastatic tumour to the pleura in men and breast
cancer in women.Together, both malignancies
account for 50- 65% of all malignant effusions. Lymphomas, tumours of the genitourinary
tract and gastrointestinal tract account for
a further 25% Pleural effusions from an
unknown primary are responsible for 15% of all
malignant pleural effusions.Few studies have
estimated the proportion of pleural effusions due to
mesothelioma: studies from 1975, 1985 and 1987
identified mesothelioma in 1/271, 3/472 and 22/592
patients, respectively, but there are no more recent
data to update this in light of the increasing incidence
of mesothelioma.
Crizele comitiale sunt evenimente paroxistice, datorate unor descarcari hipersincrone, excesive, anormale dintr-un grup de neuroni din sistemul nervos central. In functie de distributia descarcarilor, aceasta activitate a SNC poate avea diferite manifestari, mergand de la o activitate convulsiva dramatica, pana la experienta unor fenomene ce nu sunt lesne de observat din exterior.
Crizele comitiale sunt evenimente paroxistice, datorate unor descarcari hipersincrone, excesive, anormale dintr-un grup de neuroni din sistemul nervos central. In functie de distributia descarcarilor, aceasta activitate a SNC poate avea diferite manifestari, mergand de la o activitate convulsiva dramatica, pana la experienta unor fenomene ce nu sunt lesne de observat din exterior.
Przentare in cadrul sedintei din 24.11.2011 a Cercului studentesc de Neurologie si Neurochirurgie ClujNapoca.
*nu detin drepturi de autor asupra imaginilor
Single Stage Operation for Multiple Cerebral Aneurysms of the Anterior Circul...Cristina Caterina Aldea
Presented at:
Congressis 2012, Iasi - First Prize at Surgical Section
Also presented at: Medicalis Cluj-Napoca, Romania 2012; Leiden International Medical Students Conference 2013
3. ¼ din pacienţii cu epilepsie continuă să aibă crize
refractare ÎN CIUDA tratamentului medicamentos
adecvat
Calitatea vieţii alterată de :
crizele în sine
efectele adverse ale medicaţiei
SCOP: QoL prin “desfiinţarea zonei epileptogene”
4. Evaluarea candidaţilor cu indicaţie
neurochirurgicală
Echipă multidisciplinară
Studiu preoperator extensiv
monitorizare (VEEG)
evaluare neuroimagistică
neuropsihologică
5.
6. Cei mai buni candidaţi:
Criza începe într-o arie neelocventă
În unele cazuri procedeu paliativ
( frecvenţa sau severitatea crizelor)
21. Complicaţii:
Cvadranopsie superioară
Hemianopsie
Hemiplegii
Disfuncţii de memorie şi vorbire
Leziuni ale N III
ÎNSĂ: Raportat majoritatea Engell I